
Promising Formulation of New Sarclisa Subcutaneous Treatment Meets Co-Primary Endpoints in IRAKLIA Phase 3
Formulation Results from the IRAKLIA Phase 3 Study Demonstrate Promise for Subcutaneous Sarclisa in Multiple Myeloma The Formulation IRAKLIA Phase 3 study has presented encouraging results for the investigational subcutaneous…












